The new regenerative medicine advanced therapy designation is turning out to offer a major benefit of deeper regulatory interactions around manufacturing issues, according to Peter Marks, director of FDA's Center for Biological Evaluation and Research.
Like the US breakthrough designation, RMAT offers early and frequent opportunities for exchanges with regulators, with the goal of quicker reviews. But one difference is that the discussions in RMAT...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?